-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

Benzinga·08/10/2026 12:10:59
语音播报
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.